[« back]
Press Release 02.08.2005
mtm laboratories AG Establishes US Subsidiary, Naming Robert Silverman President.
Heidelberg, Germany, August, 2. mtm laboratories AG, a developer of diagnostic products for the early detection of cancer, announced today the incorporation of a US subsidiary in Westborough, Massachusetts, a suburb of Boston. The subsidiary, mtm laboratories Inc., is wholly-owned by mtm laboratories AG, Heidelberg, Germany. It will be headed by Mr. Robert Silverman, who will serve as President.
For the past 18 months, Mr. Silverman has provided strategic management consulting services to mtm through his company, RS Consulting. Prior to forming RS Consulting, Mr. Silverman served as the Senior Vice President of Commercial Operations for ViaCell, Inc. ViaCell is a biotechnology company focusing on the application of human cells as medicine in the treatment of human disease. From 1996-2001, Mr. Silverman held several senior executive positions with Cytyc Corporation, including Vice President of International and Vice President of Marketing. Cytyc is a leading medical device company focused on women's health. In addition, Mr. Silverman has held senior management positions with Pasteur-Merieux Connaught, now a division of Sanofi Aventis, and Abbott Laboratories Pharmaceutical Products Division.
The activities of the subsidiary will focus on business development and the marketing of mtm's biomarker-based products in the United States. It will increase mtm's presence and strategic position in the largest single market for products in the area of cancer early detection and diagnosis.
Peter Pack, CEO of the parent company in Heidelberg, Germany, commented: "The subsidiary will allow us to directly address the US market. With Mr. Silverman, we have identified an executive with outstanding general management and marketing expertise, and an impressive track record of successfully introducing innovative products into the medical market".
About mtm laboratories AG:
mtm laboratories AG, founded in 1999 as a spin-off of the German Cancer Research Center (DKFZ), is a privately held company based in Heidelberg, Germany. The company develops In Vitro Diagnostic test systems for the early detection and diagnosis of cancer with a focus on cervical cancer early detection, the largest early detection market in oncology.
In collaboration with DakoCytomation A/S (Denmark), IVD products that apply mtm's proprietary CINtec™ technology to cervical biopsies (CINtec™ p16ink4a Histology kit) and cytology preparations (CINtec™ p16ink4a Cytology kit) of the cervix uteri were developed and recently launched in Europe and the United States by DakoCytomation. Further biomarker-based IVD products for the rapid and automated detection of cervical cancer independent of cellular integrity are under development.
Disclaimer
Press Release 02.08.2005
mtm laboratories AG Establishes US Subsidiary, Naming Robert Silverman President.
Heidelberg, Germany, August, 2. mtm laboratories AG, a developer of diagnostic products for the early detection of cancer, announced today the incorporation of a US subsidiary in Westborough, Massachusetts, a suburb of Boston. The subsidiary, mtm laboratories Inc., is wholly-owned by mtm laboratories AG, Heidelberg, Germany. It will be headed by Mr. Robert Silverman, who will serve as President.
For the past 18 months, Mr. Silverman has provided strategic management consulting services to mtm through his company, RS Consulting. Prior to forming RS Consulting, Mr. Silverman served as the Senior Vice President of Commercial Operations for ViaCell, Inc. ViaCell is a biotechnology company focusing on the application of human cells as medicine in the treatment of human disease. From 1996-2001, Mr. Silverman held several senior executive positions with Cytyc Corporation, including Vice President of International and Vice President of Marketing. Cytyc is a leading medical device company focused on women's health. In addition, Mr. Silverman has held senior management positions with Pasteur-Merieux Connaught, now a division of Sanofi Aventis, and Abbott Laboratories Pharmaceutical Products Division.
The activities of the subsidiary will focus on business development and the marketing of mtm's biomarker-based products in the United States. It will increase mtm's presence and strategic position in the largest single market for products in the area of cancer early detection and diagnosis.
Peter Pack, CEO of the parent company in Heidelberg, Germany, commented: "The subsidiary will allow us to directly address the US market. With Mr. Silverman, we have identified an executive with outstanding general management and marketing expertise, and an impressive track record of successfully introducing innovative products into the medical market".
About mtm laboratories AG:
mtm laboratories AG, founded in 1999 as a spin-off of the German Cancer Research Center (DKFZ), is a privately held company based in Heidelberg, Germany. The company develops In Vitro Diagnostic test systems for the early detection and diagnosis of cancer with a focus on cervical cancer early detection, the largest early detection market in oncology.
In collaboration with DakoCytomation A/S (Denmark), IVD products that apply mtm's proprietary CINtec™ technology to cervical biopsies (CINtec™ p16ink4a Histology kit) and cytology preparations (CINtec™ p16ink4a Cytology kit) of the cervix uteri were developed and recently launched in Europe and the United States by DakoCytomation. Further biomarker-based IVD products for the rapid and automated detection of cervical cancer independent of cellular integrity are under development.
Disclaimer
® mtm laboratories AG, all rights reserved